PPARα in the Epigenetic Driver Seat of NAFLD: New Therapeutic Opportunities for Epigenetic Drugs?

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Dec 23

PMID 36551797

Authors

Claudia Theys

Dorien Lauwers

Claudina Perez-Novo

Wim Vanden Berghe

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a growing epidemic and the most common cause of chronic liver disease worldwide. It consists of a spectrum of liver disorders ranging from simple steatosis to NASH which predisposes patients to further fibrosis, cirrhosis and even hepatocarcinoma. Despite much research, an approved treatment is still lacking. Finding new therapeutic targets has therefore been a main priority. Known as a main regulator of the lipid metabolism and highly expressed in the liver, the nuclear receptor peroxisome proliferator-activated receptor-α (PPARα) has been identified as an attractive therapeutic target. Since its expression is silenced by DNA hypermethylation in NAFLD patients, many research strategies have aimed to restore the expression of PPARα and its target genes involved in lipid metabolism. Although previously tested PPARα agonists did not ameliorate the disease, current research has shown that PPARα also interacts and regulates epigenetic DNMT1, JMJD3, TET and SIRT1 enzymes. Moreover, there is a growing body of evidence suggesting the orchestrating role of epigenetics in the development and progression of NAFLD. Therefore, current therapeutic strategies are shifting more towards epigenetic drugs. This review provides a concise overview of the epigenetic regulation of NAFLD with a focus on PPARα regulation and highlights recently identified epigenetic interaction partners of PPARα.

Citing Articles

Exploring PPAR Gamma and PPAR Alpha's Regulation Role in Metabolism via Epigenetics Mechanism.

Malodobra-Mazur M, Oldakowska M, Dobosz T Biomolecules. 2024; 14(11).

PMID: 39595621 PMC: 11591816. DOI: 10.3390/biom14111445.

The Interplay between Liver and Adipose Tissue in the Onset of Liver Diseases: Exploring the Role of Vitamin Deficiency.

Tattoli I, Mathew A, Verrienti A, Pallotta L, Severi C, Andreola F Cells. 2024; 13(19.

PMID: 39404394 PMC: 11475612. DOI: 10.3390/cells13191631.

Loss of PPARα function promotes epigenetic dysregulation of lipid homeostasis driving ferroptosis and pyroptosis lipotoxicity in metabolic dysfunction associated Steatotic liver disease (MASLD).

Theys C, Vanderhaeghen T, Van Dijck E, Peleman C, Scheepers A, Ibrahim J Front Mol Med. 2024; 3:1283170.

PMID: 39086681 PMC: 11285560. DOI: 10.3389/fmmed.2023.1283170.

PPARs in Clinical Experimental Medicine after 35 Years of Worldwide Scientific Investigations and Medical Experiments.

Skoczynska A, Oldakowska M, Dobosz A, Adamiec R, Gritskevich S, Jonkisz A Biomolecules. 2024; 14(7).

PMID: 39062500 PMC: 11275227. DOI: 10.3390/biom14070786.

Dramatic Suppression of Lipogenesis and No Increase in Beta-Oxidation Gene Expression Are among the Key Effects of Bergamot Flavonoids in Fatty Liver Disease.

Parafati M, La Russa D, Lascala A, Crupi F, Riillo C, Fotschki B Antioxidants (Basel). 2024; 13(7).

PMID: 39061835 PMC: 11273501. DOI: 10.3390/antiox13070766.

References

Mizushima N, Komatsu M . Autophagy: renovation of cells and tissues. Cell. 2011; 147(4):728-41. DOI: 10.1016/j.cell.2011.10.026. View

Kauppinen A, Suuronen T, Ojala J, Kaarniranta K, Salminen A . Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal. 2013; 25(10):1939-48. DOI: 10.1016/j.cellsig.2013.06.007. View

Wang D, Wang B, Yang M, Liu Z, Sun J, Wang Y . Suppression of miR-30a-3p Attenuates Hepatic Steatosis in Non-alcoholic Fatty Liver Disease. Biochem Genet. 2020; 58(5):691-704. DOI: 10.1007/s10528-020-09971-0. View

Aibara D, Takahashi S, Yagai T, Kim D, Brocker C, Levi M . Gene repression through epigenetic modulation by PPARA enhances hepatocellular proliferation. iScience. 2022; 25(5):104196. PMC: 9036120. DOI: 10.1016/j.isci.2022.104196. View

Sunny N, Bril F, Cusi K . Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. Trends Endocrinol Metab. 2016; 28(4):250-260. DOI: 10.1016/j.tem.2016.11.006. View

Planavila A, Iglesias R, Giralt M, Villarroya F . Sirt1 acts in association with PPARα to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. Cardiovasc Res. 2010; 90(2):276-84. DOI: 10.1093/cvr/cvq376. View

Lee Y, Jang H, Kim S, Choi S, Khim K, Eom H . Hepatic promotes nonalcoholic fatty liver disease by suppressing . Elife. 2021; 10. PMC: 8758141. DOI: 10.7554/eLife.70472. View

Purushotham A, Schug T, Xu Q, Surapureddi S, Guo X, Li X . Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009; 9(4):327-38. PMC: 2668535. DOI: 10.1016/j.cmet.2009.02.006. View

Hervouet E, Vallette F, Cartron P . Dnmt1/Transcription factor interactions: an alternative mechanism of DNA methylation inheritance. Genes Cancer. 2011; 1(5):434-43. PMC: 3092212. DOI: 10.1177/1947601910373794. View

10.

Dahlhoff C, Desmarchelier C, Sailer M, Furst R, Haag A, Ulbrich S . Hepatic methionine homeostasis is conserved in C57BL/6N mice on high-fat diet despite major changes in hepatic one-carbon metabolism. PLoS One. 2013; 8(3):e57387. PMC: 3589430. DOI: 10.1371/journal.pone.0057387. View

11.

Hollien J, Lin J, Li H, Stevens N, Walter P, Weissman J . Regulated Ire1-dependent decay of messenger RNAs in mammalian cells. J Cell Biol. 2009; 186(3):323-31. PMC: 2728407. DOI: 10.1083/jcb.200903014. View

12.

Ishibashi S, Yamashita S, Arai H, Araki E, Yokote K, Suganami H . Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis. 2016; 249:36-43. DOI: 10.1016/j.atherosclerosis.2016.02.029. View

13.

Kim J, Wahyudi L, Kim K, Gonzalez F . PPARα activation drives demethylation of the CpG islands of the Gadd45b promoter in the mouse liver. Biochem Biophys Res Commun. 2016; 476(4):293-298. PMC: 6300979. DOI: 10.1016/j.bbrc.2016.05.115. View

14.

Sookoian S, Rosselli M, Gemma C, Burgueno A, Fernandez Gianotti T, Castano G . Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1α promoter. Hepatology. 2010; 52(6):1992-2000. DOI: 10.1002/hep.23927. View

15.

Kawahori K, Kondo Y, Yuan X, Kawasaki Y, Hanzawa N, Tsujimoto K . Ascorbic acid during the suckling period is required for proper DNA demethylation in the liver. Sci Rep. 2020; 10(1):21228. PMC: 7718234. DOI: 10.1038/s41598-020-77962-7. View

16.

Melamed P, Yosefzon Y, David C, Tsukerman A, Pnueli L . Tet Enzymes, Variants, and Differential Effects on Function. Front Cell Dev Biol. 2018; 6:22. PMC: 5844914. DOI: 10.3389/fcell.2018.00022. View

17.

Hollien J, Weissman J . Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. Science. 2006; 313(5783):104-7. DOI: 10.1126/science.1129631. View

18.

Gu T, Guo F, Yang H, Wu H, Xu G, Liu W . The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature. 2011; 477(7366):606-10. DOI: 10.1038/nature10443. View

19.

Liss K, Finck B . PPARs and nonalcoholic fatty liver disease. Biochimie. 2016; 136:65-74. PMC: 5380579. DOI: 10.1016/j.biochi.2016.11.009. View

20.

Hayashida S, Arimoto A, Kuramoto Y, Kozako T, Honda S, Shimeno H . Fasting promotes the expression of SIRT1, an NAD+ -dependent protein deacetylase, via activation of PPARalpha in mice. Mol Cell Biochem. 2010; 339(1-2):285-92. DOI: 10.1007/s11010-010-0391-z. View